Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Delivery
Return to: PBR Home | Drug Research | Drug Delivery

Drug Delivery

Impax recalls one lot of Lamotrigine Orally Disintegrating Tablet 200 mg Impax Laboratories has issued a voluntary nationwide retail level recall on August 19, 2016 for one lot of Lamotrigine Orally Disintegrating Tablet (ODT) 200 mg.
Drug Research > Drug Delivery > News
Marken secures new pharmaceutical license for Moscow depot Marken has secured a new pharmaceutical license from the Russian Federation for its Moscow depot.
Drug Research > Drug Delivery > News Supernus secures FDA tentative approval for expanded label of Trokendi XR The US Food and Drug Administration (FDA) has granted tentative approval to Supernus Pharmaceuticals' Supplemental New Drug Application (sNDA) requesting a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.
Drug Research > Drug Delivery > News
See more Drug Delivery news

Latest Drug Delivery News and Insight

View all Drug Delivery news or find news targeted to your interests
Tissue Regeneration engineered mesenchymal stromal cells advance monoclonal antibody therapy
Tissue Regeneration Therapeutics announced that a team of Canadian researchers has for the first time shown that TRT's engineered mesenchymal stromal cell product (eTXP) can be used to deliver therapeutically useful monoclonal antibodies (mAbs) more effectively than administration of the mAbs themselves.
Drug Research > Drug Delivery > News
Molecular flexibility demonstrated to help pharmaceutical drugs bind to their targets
Scientists have discovered an alternative way to create a stronger binding between pharmaceutical drugs and the part of the body they are targeting – a development that can be used to fight a variety of diseases, including breast cancer.
Drug Research > Drug Delivery > News
Nymox unveils major progress in evidence for efficacy of prostate drug
Nymox Pharmaceutical has announced major progress in the evidence for the safety and efficacy of fexapotide, the Company's Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate cancer.
Drug Research > Drug Delivery > News
Valeant Pharmaceuticals relaunches generic ofloxacin otic solution
Valeant Pharmaceuticals International has relaunched its generic ofloxacin otic solution to treat bacterial ear infections.
Drug Research > Drug Delivery > News
Teva launches generic Gleevec tablets in US
Teva Pharmaceutical Industries has launched the generic equivalent to Gleevec1(imatinib mesylate) tablets,100 mg and 400 mg, in the US for multiple indications approved by the FDA.
Drug Research > Drug Delivery > News
Quantum Pharma launches Mucodis Rectal Gel
Quantum Pharma has launched its Mucodis Rectal Gel for the prevention and treatment of rectal mucositis, a common side effect of chemotherapy and radiotherapy in cancer patients.
Drug Research > Drug Delivery > News
Puma submits NDA for PB272 to FDA for extended adjuvant treatment of HER2-Positive early stage breast cancer
Puma Biotechnology has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate PB272 (neratinib) for the extended adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab (Herceptin)-based therapy.
Drug Research > Drug Delivery > News
Citron Pharma launches Rosuvastatin calcium tablets
Citron Pharma confirmed that its licensing partner received final approval from the U.S. Food and Drug Administration (FDA) for their Abbreviated New Drug Application (ANDA) for Rosuvastatin Calcium 5, 10, 20 and 40 mg tablets, the generic version of AstraZeneca's CRESTOR (rosuvastatin calcium) tablets.
Drug Research > Drug Delivery > News
West-Ward Pharmaceuticals launches generic Xeloda tablets 150 mg and 500 mg in US
Hikma Pharmaceuticals' wholly owned US affiliate, West-Ward Pharmaceuticals has launched Capecitabine Tablets 150 mg and 500 mg, the generic equivalents to Xeloda1 Tablets.
Drug Research > Drug Delivery > News
ProQR secures FDA fast track designation for QR-010 to treat Cystic Fibrosis
ProQR Therapeutics has received Fast Track designation from the Food and Drug Administration (FDA) for its molecule QR-010 that is in clinical development for the treatment of patients with CF due to the ∆F508 mutation.
Drug Research > Drug Delivery > News
View all Drug Delivery news or find news targeted to your interests